Primary Cardiovascular Risk Prevention With Aspirin in Chronic Kidney Disease Patients


The objective of the study is to examine whether the use of low-dose aspirin (75-100 mg / day) reduces the risk of cardiovascular disease in patients with chronic kidney disease (stage 3 or 4).

Full Title of Study: “Effect of Aspirin in Primary Prevention of Cardiovascular Risk in Patients With Chronic Kidney Disease (AASER Study)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2015

Detailed Description

Hypothesis: The low-dose aspirin reduces cardiovascular risk in patients with chronic kidney disease without increasing the risk of bleeding


  • Drug: Aspirin
    • 100 mg/day of aspirin

Arms, Groups and Cohorts

  • Active Comparator: aspirin
    • Aspirin dosage 100 mg/day
  • No Intervention: standard medication
    • the patients will continue with standard medication

Clinical Trial Outcome Measures

Primary Measures

  • Cardiovascular events
    • Time Frame: five years
    • To assess the benefit of treatment with low-dose aspirin in the primary prevention of cardiovascular events (incidence of the composite endpoint: death, acute coronary syndrome, stroke or nonfatal acute peripheral arteriopathy disease) in patients with chronic kidney disease who are not in dialysis or renal transplant.

Secondary Measures

  • Major bleeding
    • Time Frame: five years
    • -Evaluate the incidence of major bleeding requiring hospitalization
  • antiinflammatory effects of aspirin
    • Time Frame: five years
    • -to analyze the antiinflammatory effect of aspirin in patients with chronic kidney disease

Participating in This Clinical Trial

Inclusion Criteria

  • sign informed consent – males 45-79 years or females 55-79 years. -Stage 3 or 4 CKD (estimated GFR by MDRD abbreviated, between 15 and 60 ml / min/1.73 m2) - Exclusion Criteria:

  • a previous cardiovascular event: cardiac arrhythmias, cardiac arrest, angina or acute myocardial infarction, stroke, carotid stenosis of more than 50%, peripheral vascular arteriopathy documented – hospitalization for any cause in the last three months prior to inclusion in the study allergy of acetyl-salicylic acid – coagulopathy from any cause – thrombocytopenia <150,000 platelets – liver disease from any cause – Infection by hepatitis B virus, hepatitis C or HIV – immunosuppressive treatment within 12 weeks before inclusion in the study – Major bleeding events including gastrointestinal bleeding and brain hemorrhage. – hemoglobinopathies (eg sickle cell disease or thalassemia of any kind) – active malignancy (except non-melanoma skin cancer). May be included in the study patients with malignant neoplasia who have remained disease-free for at least the previous 5 years. – uncontrolled inflammatory disease or symptomatic (eg rheumatoid arthritis, lupus, Chrom disease or bowel inflammatory disease) – hemolysis – treatment with oral anticoagulation and / or antiplatelet therapy prior. – poorly controlled hypertension (> 160/90 mm Hg) -pregnancy or breast- – women of childbearing potential not using effective contraception.

Gender Eligibility: All

Minimum Age: 45 Years

Maximum Age: 79 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales
  • Provider of Information About this Clinical Study
    • Principal Investigator: Jose Luño Fernandez, Headmaster of Nephrology Department – Fundación de Ayuda a la Investigación sobre la Hipertensión, Riesgo Cardiovascular y Enfermedades Renales
  • Overall Official(s)
    • JOSE LUÑO, MD, PhD, Principal Investigator, Hospital General Universitario Gregorio Marañon
  • Overall Contact(s)
    • JOSE LUÑO, MD, PHD, 0034915868319,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.